Conversely, in cancer, tumors may exploit both proteins: YY1 can promote immune evasion by upregulating immune checkpoint molecules (e.g., PD-L1), while RKIP downregulation may enhance pro-survival pathways (223). This evidence concerns the gene YY1 and cancer.